Unless otherwise stated in this report, all data refers to the group. Figures in parentheses are for the corresponding periods in 2010.

POSITIVE DEVELOPMENT IN ABSTRAL® SALES AND OREXO’S PROPRIETARY PROGRAMS WHILE THE OX-CLI AND OX-ESI PROJECTS ARE ABORTED

During the year

· Net revenues amounted to 199.6 MSEK (210.5).
· The loss after tax was MSEK -392.0 (-89.2).
· Impairment of acquired development related to the OX-CLI and OX-ESI projects amounted to MSEK 233
· Operating income adjusted for impairment of acquired development amounted to MSEK ‑120.3 (‑56.0).
· Cash flow from operating activities amounted to MSEK -117.2 (-43.0).
· The loss per share amounted to SEK -14.43 (-3.81).
· Cash and cash equivalents at the end of the year, amounted to MSEK 246.9 (MSEK 135.8).
· Royalty revenues from Abstral® sales increased to MSEK 70.5 (42.2).
· Abstral was approved and introduced in the US and Canada.
· A new share issue worth approximately MSEK 245, before transaction costs,...